Skip to main content

10-12-2019 | Haematology | Video

ASH 2019 | Blinatumomab superior to chemotherapy after first relapse in young ALL patients

Patrick Brown shares his phase 3 trial findings pitting blinatumomab against chemotherapy as post-reinduction therapy prior to allogeneic hematopoietic stem cell transplant in children and young patients with B-cell acute lymphoblastic leukaemia (4:04).  

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits